Great to see our stellar trainees present their clinical trial concepts at the @etop_ibcsg residential workshop! Well done to to them & thanks to the mentors for fostering our young ⭐️ @cancertrials_ie @ICATProgramme @CancerCentreIre @CancerInstIRE @peters_solange @RolfStahel

Kicking off the @etop_ibcsg Annual Meeting, with: - Keynote lectures @g_mountzios @FordePatrick #PaulBaas #MauricePerol - Translational outputs #StephenFinn - Growing participation across 🇪🇺🇮🇪 @RolfStahel @CancerCentreIre @CancerInstIRE @cancertrials_ie @LungCommunity #LCSM

Our ETOP Annual Meeting 2025 just started with amazing keynote presentations.

Soon finishing day 2 of our 14th ETOP Residential Workshop with great presentations from the faculty, very interesting project proposals from our participants and lively discussions.

Our 14th ETOP Residential Workshop started this morning in Rome with a great faculty and 27 participants from all over Europe.

🆕 article in press: primary results from the randomized phase II TOUCH trial of neoadjuvant palbociclib + letrozole vs paclitaxel combo with trastuzumab + pertuzumab in pts with HR+/HER2+ EBC @LMalorni https://t.co/euPGLKqwUD

👏👏Bravo @LMalorni @etop_ibcsg This important study shows that endocrine therapy and CDK4+ HER2 targeting therapy in HR+ HER2+ is highly effective with similar rates of pCR to taxol+TP! Supports #Patina study & also removing #chemotherapy in the early stage HER2+ HR+ setting.

Just presented at #ESMO25 by super @fedrophd updated data of the #POSITIVE trial showing reassuring evidence to support temporary interruption of endocrine therapy to have a #pregnancy in patients with prior history of low/intermediate risk #BreastCancer @OncoAlert @etop_ibcsg

“We made it!” @fedrophd presenting the updated results of POSITIVE. After 71 months of median follow-up, temporary interruption of ET for pregnancy was not associated with worse BC outcomes. Super news for patients! 👏 groups & investigators for this academic effort. #ESMO25

POSITIVE trial update #esmo2025 ! Pausing endocrine therapy to pursue pregnancy does not increase the risk of breast cancer recurrence after a median follow-up of 6 years. Key reassurance for young survivors!

Rolf Stahel - @etop_ibcsg a community with a common goal #lcsm #ESMO25 @myESMO

Rolf Stahel - such a well deserved winner of the @myESMO lifetime achievement award 🎉👏🎉 @etop_ibcsg #lcsm #ESMO25

Our foundation‘s president Rolf Stahel receiving the @myESMO Livetime Achievements Award at #ESMO2025.

Join us at #ESMO2025 for the updated results of the IBCSG 48-14 / BIG 8-13 POSITIVE trial today, Oct 17!🕑14:00 CEST | 📍 Munich Auditorium – CityCube B @BIGxResearch

We are happy to announce that the ETOP Slide deck of 2025 WCLC is now available online: https://t.co/fBNyKFolhB

REMINDER: Register now for the upcoming ETOP Annual Meeting in Rome. Registration deadline is 30 August 2025.

New pub 📢 The #POSITIVEtrial manuscript led by @IDemeestere has been published in The Breast! It explores hormonal factors predictive of fertility in young women with #breastcancer interrupting #endocrinetherapy to try for pregnancy. @etop_ibcsg 🔗 https://t.co/xgDx9Eb7QT

✨Encouraging all budding thoracic oncology stars to attend the ETOP Residential Workshop 📅 29 - 31 Oct 2025 📍 Rome 🇮🇹 Two days of the very best thoracic onc education & hands-on training on your research concepts! Apply by Friday👇 @etop_ibcsg @peters_solange #LCSM

New results from the IBCSG POSITIVE trial highlight the need to assess hormonal factors when advising breast cancer patients pausing endocrine therapy for pregnancy. Published in @TheBreastOnline. https://t.co/vpy9iHu4MD

ESMO has announced the recipients of the 2025 ESMO Society Awards in recognition of their significant contributions to advancing the field of #oncology and supporting fellow professionals in their careers. 🔗 https://t.co/cA0FaG4QYM